These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24884602)

  • 1. Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies.
    Howard C; Noe A; Skerjanec A; Holzhauer B; Wernsing M; Ligueros-Saylan M; Thuren T
    Cardiovasc Diabetol; 2014 May; 13():94. PubMed ID: 24884602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial.
    Hensen J; Howard CP; Walter V; Thuren T
    Diabetes Metab; 2013 Dec; 39(6):524-31. PubMed ID: 24075453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
    Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus.
    Noe A; Howard C; Thuren T; Taylor A; Skerjanec A
    Clin Ther; 2014 Nov; 36(11):1625-37. PubMed ID: 25240532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
    Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM
    J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
    Ridker PM; Howard CP; Walter V; Everett B; Libby P; Hensen J; Thuren T;
    Circulation; 2012 Dec; 126(23):2739-48. PubMed ID: 23129601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
    Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
    N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
    Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
    J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance.
    Choudhury RP; Birks JS; Mani V; Biasiolli L; Robson MD; L'Allier PL; Gingras MA; Alie N; McLaughlin MA; Basson CT; Schecter AD; Svensson EC; Zhang Y; Yates D; Tardif JC; Fayad ZA
    J Am Coll Cardiol; 2016 Oct; 68(16):1769-1780. PubMed ID: 27737744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
    Rissanen A; Howard CP; Botha J; Thuren T;
    Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.
    Alten R; Gomez-Reino J; Durez P; Beaulieu A; Sebba A; Krammer G; Preiss R; Arulmani U; Widmer A; Gitton X; Kellner H
    BMC Musculoskelet Disord; 2011 Jul; 12():153. PubMed ID: 21736751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
    Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
    J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
    Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
    Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.
    Schlesinger N; Mysler E; Lin HY; De Meulemeester M; Rovensky J; Arulmani U; Balfour A; Krammer G; Sallstig P; So A
    Ann Rheum Dis; 2011 Jul; 70(7):1264-71. PubMed ID: 21540198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of canakinumab in the cryopyrin-associated periodic syndrome.
    Lachmann HJ; Kone-Paut I; Kuemmerle-Deschner JB; Leslie KS; Hachulla E; Quartier P; Gitton X; Widmer A; Patel N; Hawkins PN;
    N Engl J Med; 2009 Jun; 360(23):2416-25. PubMed ID: 19494217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
    de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
    Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
    Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
    Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia.
    Rees DC; Kilinc Y; Unal S; Dampier C; Pace BS; Kaya B; Trompeter S; Odame I; Mahlangu J; Unal S; Brent J; Grosse R; Fuh BR; Inusa BPD; Koren A; Leblebisatan G; Levin C; McNamara E; Meiser K; Hom D; Oliver SJ
    Blood; 2022 Apr; 139(17):2642-2652. PubMed ID: 35226723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.